Heron Therapeutics, Inc. (HRTX) Q1 2023 Earnings Call Transcript

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2023 Earnings Convention Name Could 11, 2023 4:30 PM ET

Firm Contributors

Craig Collard – Chief Govt Officer

David Szekeres – Govt Vice President & Chief Working Officer

Convention Name Contributors

Brandon Folkes – Cantor Fitzgerald

Rohit Bhasin – Needham & Firm

Carl Byrnes – Northland


Good day, women and gents, and thanks for standing by. Welcome to the Heron Therapeutics Q1 2023 Earnings Convention. Earlier than we start, I wish to remind you that this name will include forward-looking statements, regarding Heron’s future expectations, plans, prospects, company technique and efficiency, which represent forward-looking statements for the needs of the secure harbor provision beneath the Personal Securities Litigation Reform Act of 1995.

Precise outcomes could differ materially from these indicated by these forward-looking statements because of varied vital elements, together with these mentioned in Heron’s filings with the SEC. As well as, any forward-looking statements symbolize Heron’s views solely as of the date of this webcast and shouldn’t be relied upon, as representing Heron’s views as of any subsequent date. Heron particularly disclaims any obligations to replace such statements.

Now, I am going to flip the decision over to Craig.

Craig Collard

Thanks, operator. Good afternoon, everybody, and welcome to the Heron Therapeutics First Quarter 2023 Earnings Name. I am Craig Collard, the brand new CEO of Heron Therapeutics, and I am thrilled to be main this group, as we proceed to make headway within the hospital and oncology markets.

At this time, I am going to present an summary of our latest efficiency, spotlight key achievements, however extra importantly, give some perception into my evaluation of the enterprise in my first 4 weeks and talk about our strategic imaginative and prescient shifting ahead. Complete product web revenues for the primary quarter had been $29.6 million, up from $23.5 million in the identical quarter final 12 months, a rise of over 26%. We proceed to make regular